U.S. markets open in 3 hours 47 minutes
  • S&P Futures

    3,803.75
    +13.25 (+0.35%)
     
  • Dow Futures

    30,894.00
    +66.00 (+0.21%)
     
  • Nasdaq Futures

    13,082.00
    +96.50 (+0.74%)
     
  • Russell 2000 Futures

    2,142.80
    -4.50 (-0.21%)
     
  • Crude Oil

    53.50
    +0.52 (+0.98%)
     
  • Gold

    1,853.00
    +12.80 (+0.70%)
     
  • Silver

    25.44
    +0.12 (+0.49%)
     
  • EUR/USD

    1.2129
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.0920
    0.0000 (0.00%)
     
  • Vix

    22.23
    -2.11 (-8.67%)
     
  • GBP/USD

    1.3698
    +0.0064 (+0.47%)
     
  • USD/JPY

    103.7800
    -0.1120 (-0.11%)
     
  • BTC-USD

    34,788.97
    -1,105.29 (-3.08%)
     
  • CMC Crypto 200

    686.53
    -28.66 (-4.01%)
     
  • FTSE 100

    6,724.45
    +11.50 (+0.17%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

Recap: Biohaven Pharmaceutical Q3 Earnings

Benzinga Insights
·1 min read

 

Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 30.88% year over year to ($2.67), which beat the estimate of ($2.89).

Revenue of $17,664,000 up by 0.00% year over year, which missed the estimate of $19,840,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 09, 2020

View more earnings on BHVN

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/bhvn/mediaframe/41093/indexl.html

Recent Stock Performance

52-week high: $89.46

Company's 52-week low was at $26.56

Price action over last quarter: Up 40.88%

Company Profile

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.